Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.

The Journal of Infectious Diseases
Nicaise NdembiDevelopment of Antiretroviral Treatment in Africa Virology Group and Trial Team

Abstract

We investigated virological response and the emergence of resistance in the Nevirapine or Abacavir (NORA) substudy of the Development of Antiretroviral Treatment in Africa (DART) trial. Six hundred symptomatic antiretroviral-naive human immunodeficiency virus (HIV)-infected adults (CD4 cell count, <200 cells/mm(3)) from 2 Ugandan centers were randomized to receive zidovudine-lamivudine plus abacavir or nevirapine. Virology was performed retrospectively on stored plasma samples at selected time points. In patients with HIV RNA levels >1000 copies/mL, the residual activity of therapy was calculated as the reduction in HIV RNA level, compared with baseline. Overall, HIV RNA levels were lower in the nevirapine group than in the abacavir group at 24 and 48 weeks (P < .001), although no differences were observed at weeks 4 and 12. Virological responses were similar in the 2 treatment groups for baseline HIV RNA level <100,000 copies/mL. The mean residual activity at week 48 was higher for abacavir in the presence of the typically observed resistance pattern of thymidine analogue mutations (TAMs) and M184V (1.47 log(10) copies/mL) than for nevirapine with M184V and nonnucleoside reverse-transcriptase inhibitor mutations, whether accom...Continue Reading

Citations

May 25, 2013·The Journal of Infectious Diseases·Mina C HosseinipourJean B Nachega
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·Estevão Portela NunesMauro Schechter
Dec 3, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Myres W TilghmanDavey M Smith
Jul 20, 2011·Antimicrobial Agents and Chemotherapy·D T DunnUNKNOWN DART Virology and Trial Team
Mar 19, 2014·The Journal of Antimicrobial Chemotherapy·R L GoodallUNKNOWN DART Virology Group and Trial Teams
May 17, 2013·Bulletin of the World Health Organization·James H McMahonMichael R Jordan
Dec 20, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ravindra K GuptaUNKNOWN DART Virology Group and Trial Team
Jul 21, 2015·Journal of Multivariate Analysis·Larissa A MatosVictor H Lachos
Oct 10, 2014·Statistical Methods in Medical Research·Aldo M GarayVictor H Lachos
Mar 20, 2018·Statistical Methods in Medical Research·Luis M CastroCristian L Bayes
Aug 6, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Fred LyagobaUNKNOWN DART Virology and Trial Team
Nov 10, 2010·AIDS·Patricia E Fast, Pontiano Kaleebu
Apr 2, 2013·The Cochrane Database of Systematic Reviews·Muki S SheyCharles Shey Wiysonge
May 26, 2012·Current Opinion in HIV and AIDS·Veronica MillerAndy Stergachis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

© 2022 Meta ULC. All rights reserved